- BMRN -0.65%
BioMarin Pharmaceutical Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Yahoo Finance · 2 weeks ago
Search results
- 80.50Add to watchlist-0.53 (-0.65%)At close: Mon. May 13, 2024 4:00 PM EDT · Nasdaq Real Time Price (USD) · Market closed
- Open81.24High81.57Low80.37
- Mkt Cap15.29BP/E (TTM)75.94Div & YieldN/A & N/A
- Prev. Close81.0352 Wk. Low76.0252 Wk. High99.56
What analysts are sayingTop storiesRelated stocks
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an...
We leverage expertise in genetics and genomics to create new medicines for people with serious medical conditions. Learn more about our products and pipeline.
Learn how we leverage deep expertise in genetics to research and develop transformative medicines for people living with serious medical conditions around the world.
Get the latest Biomarin Pharmaceutical Inc (BMRN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...
Nov 1, 2023 · Nov 1, 2023. • Full-year 2023 Total Revenues and Earnings Per Share Financial Guidance Narrowed; VOXZOGO ® and ROCTAVIAN ® Net Product Revenue Guidance Adjusted for Full-year 2023. • VOXZOGO Now Approved for Children without Age Restrictions in the United States and for Children Aged 4 Months and Older in Europe.
Aug 24, 2022 · SAN RAFAEL, Calif., Aug. 24, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the European Commission (EC) has granted conditional marketing authorization (CMA) to ROCTAVIAN™ (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult ...
Jun 29, 2023 · SAN RAFAEL, Calif., June 29, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced that the United States Food and Drug Administration (FDA) approved ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) gene therapy for the treatment ...
